---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-040183"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:12:03.571202+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Karyopharm grants annual equity awards to CEO Paulson and CFO Mason under 2022 Plan

## Summary
- CEO Richard Paulson receives 252,000 time-based RSUs and 252,000 target PSUs (0-200% vesting).
- CFO Michael Mason receives 95,000 time-based RSUs and 80,000 target PSUs.
- PSU vesting tied 33% each to: 3-year revenue, 3 clinical milestones, and relative TSR vs Nasdaq Biotech Index.
- Clinical milestone PSUs have a 1-year minimum vesting; performance measured over 3-year periods.

## SEC filing metadata
- accession: 0001193125-23-040183
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/0001193125-23-040183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/d459493d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-040183
- JSON: https://secwatch.observer/filing/0001193125-23-040183.json
- Plain text: https://secwatch.observer/filing/0001193125-23-040183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.